US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Ionis Pharmaceuticals, Inc.

< Previous 1 2 Next >
News headline image
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis reports second quarter 2026 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to hold second quarter 2026 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to host 2026 virtual Annual Meeting of Stockholders
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis reports first quarter 2026 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to hold first quarter 2026 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis announces changes to Board of Directors
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
News headline image
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
< Previous 1 2 Next >